Pancreatic Cancer Research

ResearcherUniversity of MichiganActive in the last 2 years

Jiaqi Shi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-4893-1587; OpenAlex author ID A5081215027, A5132833960; NIH RePORTER profile ID 7078074. Sources: OpenAlex.

Their work

Papers
32 (first author 4, last author 8)
Trials
0
Grants
3
Labs led
2
Collaborators
122
Papers, trials and grants by year

2012: 1 grant · 2013: 1 paper · 2014: none · 2015: 1 paper · 2016: 1 paper · 2017: none · 2018: 2 papers · 2019: 4 papers · 2020: 3 papers · 2021: 2 papers, 1 grant · 2022: 3 papers · 2023: 3 papers · 2024: 5 papers · 2025: 2 papers · 2026: 5 papers, 1 grant

Papers 32

  1. Elevated T Cell Immunoreceptor with Ig and ITIM Domains (TIGIT) Expression and Immune Cell Dysfunction Characterize Complex Proteins Associated With SET1 (COMP… Last author DOI 10.1016/j.modpat.2026.100972↗
  2. A stromal PAI1-tPA axis orchestrates immunosuppression in pancreatic cancer. Co-author DOI 10.1126/sciadv.aea6734↗
  3. Wilms Tumor 1-Expressing Stromal Cells Promote Pancreatic Cancer Progression. Co-author DOI 10.1158/0008-5472.can-25-1014↗
  4. Longitudinal Analysis of Matched Patient Biospecimens Reveals Neural Reprogramming of Cancer-Associated Fibroblasts Following Chemotherapy in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-26-0823↗
  5. Asynchronous Evolution of Epithelium and Stroma Differentiates Precursor Lesions from Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-25-2001↗
  6. Primary and metastatic cellular landscapes in human pancreatic cancer. Co-author DOI 10.1016/j.isci.2025.113012↗
  7. DUSP6 is upregulated in metastasis and influences migration and metabolism in pancreatic cancer cells. Co-author DOI 10.1038/s41598-025-12967-8↗
  8. Insights into the mechanisms driven by H3K4 KMTs in pancreatic cancer. Co-author DOI 10.1042/bcj20230374↗
  9. KRT17high/CXCL8+ Tumor Cells Display Both Classical and Basal Features and Regulate Myeloid Infiltration in the Pancreatic Cancer Microenvironment. Co-author DOI 10.1158/1078-0432.ccr-23-1421↗
  10. Clinical Evaluation of the Pancreatic Cancer Microenvironment: Opportunities and Challenges. Last author DOI 10.3390/cancers16040794↗
  11. A Comparison of Spatial and Phenotypic Immune Profiles of Pancreatic Ductal Adenocarcinoma and Its Precursor Lesions. First author DOI 10.3390/ijms25052953↗
  12. Unveiling the Molecular Landscape of Pancreatic Ductal Adenocarcinoma: Insights into the Role of the COMPASS-like Complex. Last author DOI 10.3390/ijms25105069↗
  13. KMT2D links TGF-β signaling to noncanonical activin pathway and regulates pancreatic cancer cell plasticity. Last author DOI 10.1002/ijc.34528↗
  14. Uridine-derived ribose fuels glucose-restricted pancreatic cancer. Co-author DOI 10.1038/s41586-023-06073-w↗
  15. Genome, Metabolism, or Immunity: Which Is the Primary Decider of Pancreatic Cancer Fate through Non-Apoptotic Cell Death? First author DOI 10.3390/biomedicines11102792↗
  16. KDM6A Regulates Cell Plasticity and Pancreatic Cancer Progression by Noncanonical Activin Pathway. Last author DOI 10.1016/j.jcmgh.2021.09.014↗
  17. Pathologic Examination of Pancreatic Specimens Resected for Treated Pancreatic Ductal Adenocarcinoma: Recommendations From the Pancreatobiliary Pathology Socie… Co-author DOI 10.1097/pas.0000000000001853↗
  18. KDM6A Loss Recruits Tumor-Associated Neutrophils and Promotes Neutrophil Extracellular Trap Formation in Pancreatic Cancer. Last author DOI 10.1158/0008-5472.can-22-0968↗
  19. Loss of activating transcription factor 3 prevents KRAS-mediated pancreatic cancer. Co-author DOI 10.1038/s41388-021-01771-z↗
  20. Towards a More Standardized Approach to Pathologic Reporting of Pancreatoduodenectomy Specimens for Pancreatic Ductal Adenocarcinoma: Cross-continental and Cro… First author DOI 10.1097/pas.0000000000001723↗
  21. Phase 2 Trial of Neoadjuvant FOLFIRINOX and Intensity Modulated Radiation Therapy Concurrent With Fixed-Dose Rate-Gemcitabine in Patients With Borderline Resec… Co-author DOI 10.1016/j.ijrobp.2019.08.057↗
  22. Tumour-reprogrammed stromal BCAT1 fuels branched-chain ketoacid dependency in stromal-rich PDAC tumours. Co-author DOI 10.1038/s42255-020-0226-5↗
  23. Needle-compatible miniaturized optoelectronic sensor for pancreatic cancer detection. Co-author DOI 10.1126/sciadv.abc1746↗
  24. Macrophage-Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic Cancer. Co-author DOI 10.1016/j.cmet.2019.02.001↗
  25. Expression and prognostic value of NSD1 and SETD2 in pancreatic ductal adenocarcinoma and its precursor lesions. Last author DOI 10.1016/j.pathol.2019.02.005↗
  26. CSN6 expression is associated with pancreatic cancer progression and predicts poor prognosis. Co-author DOI 10.1080/15384047.2019.1632143↗
  27. Inhibition of ATM Increases Interferon Signaling and Sensitizes Pancreatic Cancer to Immune Checkpoint Blockade Therapy. Co-author DOI 10.1158/0008-5472.can-19-0761↗
  28. Profiling Heterogeneous Circulating Tumor Cells (CTC) Populations in Pancreatic Cancer Using a Serial Microfluidic CTC Carpet Chip. Co-author DOI 10.1002/adbi.201800228↗
  29. HNF1A is a novel oncogene that regulates human pancreatic cancer stem cell properties. Co-author DOI 10.7554/elife.33947↗
  30. Alterations of Epigenetic Regulators in Pancreatic Cancer and Their Clinical Implications. First author DOI 10.3390/ijms17122138↗
  31. Implication of suspicious cytology in endoscopic ultrasound-guided fine-needle aspiration for pancreatic cancer. Co-author DOI 10.1007/s12029-014-9681-0↗
  32. Extracellular DNA in pancreatic cancer promotes cell invasion and metastasis. Last author DOI 10.1158/0008-5472.can-12-3287↗

Grants 3

  1. Defining epigenetic signaling to reshape pancreatic tumor microenvironment R37CA262209↗
  2. Linking epigenetic regulation and TGF-β signaling in pancreatic cancer K08CA234222↗
  3. Translational Control by eIF3f in Pancreatic Cancer R03CA158895↗

Closest collaborators

The 25 strongest of 122 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marina Pasca di Magliano · 14 shared papers, 2019–2026 · strength 2.28
  2. Timothy L. Frankel · 9 shared papers, 2019–2026 · strength 1.62
  3. Filip Bednar · 6 shared papers, 2024–2026 · strength 1.20
  4. Eileen S. Carpenter · 6 shared papers, 2023–2026 · strength 1.10
  5. Vaibhav Sahai · 7 shared papers, 2018–2026 · strength 1.01
  6. Costas Andreas Lyssiotis · 5 shared papers, 2019–2026 · strength 0.84
  7. Erfaneh Barar · 2 shared papers, 2023–2024 · strength 0.75
  8. Padma Kadiyala · 4 shared papers, 2024–2026 · strength 0.74
  9. Ahmed M. Elhossiny · 4 shared papers, 2024–2026 · strength 0.74
  10. Howard C. Crawford · 6 shared papers, 2018–2025 · strength 0.73
  11. Yaqing Zhang · 3 shared papers, 2026 · strength 0.72
  12. Emily L. Lasse Opsahl · 3 shared papers, 2025–2026 · strength 0.66
  13. Julianne M. Szczepanski · 2 shared papers, 2024–2026 · strength 0.57
  14. Martín E. Fernández-Zapico · 2 shared papers, 2024–2026 · strength 0.49
  15. Mats E. Ljungman · 4 shared papers, 2018–2023 · strength 0.47
  16. Nina G. Steele · 3 shared papers, 2021–2025 · strength 0.44
  17. Mariana T. Ruckert · 2 shared papers, 2025–2026 · strength 0.44
  18. Brian D. Griffith · 2 shared papers, 2024–2026 · strength 0.44
  19. Valerie Gunchick · 3 shared papers, 2020–2025 · strength 0.41
  20. Zhujun Yi · 3 shared papers, 2022–2023 · strength 0.41
  21. Samantha B. Kemp · 3 shared papers, 2019–2025 · strength 0.39
  22. Marzieh Jamali · 1 shared paper, 2024 · strength 0.36
  23. Jorge D. Machicado · 2 shared papers, 2024–2026 · strength 0.34
  24. Hari Nathan · 2 shared papers, 2020–2024 · strength 0.33
  25. Katelyn L. Donahue · 2 shared papers, 2024–2025 · strength 0.32

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.